Lebanon-based Provention Bio Inc. a clinical-stage biopharmaceutical company, announced it has appointed new members to its executive management team. Lebanon-based Provention Bio Inc. a ...

Provention Bio, a biopharmaceutical company based in Red Bank, recently announced the closing of a $35 million equity investment from Bridgewater-based Sanofi US. The deal is part of a previously ...

Tourlite Capital Management, an investment management company, released its fourth-quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, Tourlite Fund Founder ...

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big ...

Provention Bio Inc (NASDAQ:PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ:SNY) announced plans to acquire the biopharmaceutical company. What Happened: Sanofi and Provention Bio entered ...

Sanofi proposed to acquire Provention Bio for $2.9 billion in cash at a 273% premium over the previous closing price (before the deal announcement). The acquisition is expected to be a net positive ...

-If Approved Teplizumab will be the First Disease-Modifying Therapy for Type 1 Diabetes - Certain statements in this press release are forward-looking, including but not limited to, statements ...

Things can change quickly in the volatile biotech industry. Just ask Provention Bio (NASDAQ: PRVB). The autoimmune disease-focused drugmaker seemed on the verge of earning a major regulatory approval ...

Provention Bio Inc (NASDAQ:PRVB) shares are trading higher by 20.6% to $5.97 Thursday morning after the company announced it has entered into a co-promotion agreement with Sanofi U.S. for the launch ...

One of the most important things I like to see in biotech is innovation. Provention Bio did not disappoint in this regard. That's because it posted some really positive results for its At-Risk study ...

Provention Bio's leading candidate and exciting pipeline show real potential. But the biotech could face clinical, regulatory, and funding problems. The headwinds related to teplizumab have played a ...